Secondary clinical outcomes
| Outcome | IVIG (n=10) | Placebo (n=8) | Overall (n=18) | |
| During hospital stay | ||||
| Duration of ventilation | Median (IQR) | 2.5 (2.0–3.5) (n=4) | 2.0 (2.0–3.0) (n=5) | 2.0 (2.0–3.0) (n=9) |
| Length of ICU stay | Median (IQR) | 4.0 (3.0–6.0) (n=5) | 5.0 (2.0–10.0) (n=5) | 4.5 (3.0–6.8) (n=10) |
| Length of hospitalisation for acute care | Median (IQR) | 12.0 (8.0–27.0) (n=9) | 8.0 (6.5–14.0) (n=7) | 11.0 (7.8–19.5) (n=16) |
| 6 months post randomisation | ||||
| New diagnosis of epilepsy since discharge | n (%) | 1 (10%) | 1 (13%) | 2 (11%) |
| Anti-epileptic treatment since discharge | n (%) | 1 (10%) | 1 (13%) | 2 (11%) |
| 12 months post randomisation | ||||
| New diagnosis of epilepsy since discharge | n (%) | 0 (0%) | 1 (13%) | 1 (6%) |
| Antiepileptic treatment since discharge | n (%) | 0 (0%) | 0 (0%) | 0 (0%) |
ICU, intensive care unit.